AVIR Q4 2020 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M

Gross Profit

$35M71.5% margin

Operating Income

$21M42.5% margin

Net Income

$21M42.5% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$319M

Free Cash Flow

$319M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$864M

Total Liabilities

$316M

Stockholders' Equity

$548M

Cash & Equivalents

$850M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$0	—
Gross Profit	$35M	-$4,000	+869775.0%
Operating Income	$21M	-$5M	+534.8%
Net Income	$21M	-$5M	+543.7%